United States Drug Eluting Stent Market Insight
Published: 29 June 2026 | Report Format: Electronic (PDF) | Author: Govind and Krishna
The United States Drug Eluting Stent Market is projected to grow at a CAGR of around 6.8%, driven by the increasing prevalence of coronary artery disease and rising demand for improved long-term clinical outcomes.
United States Drug Eluting Stent Market Forecasts to 2035
- The United States Drug Eluting Stent Market size was estimated at approximately USD 3.85 Billion in 2025.
- The market is expected to grow at a CAGR of around 6.8% from 2025 to 2035.
- The United States Drug Eluting Stent Market is projected to reach approximately USD 7.45 Billion by 2035.
Notable Insight the United States Drug Eluting Stent Market
- Based on stent type, Everolimus-Eluting Stents account for nearly 43% of market revenue in 2025, supported by their superior safety profile, reduced restenosis rates, and broad physician preference.
- Based on end user, Hospitals represent approximately 71% of total market demand, driven by the increasing number of percutaneous coronary intervention (PCI) procedures performed across the United States.
- The market is increasingly influenced by next-generation polymer technologies, bioresorbable coatings, AI-assisted cardiovascular imaging, and precision interventional cardiology, with advanced drug-eluting stent technologies accounting for more than 48% of newly implanted coronary stents in 2025.
- Growing investments in cardiovascular care infrastructure, catheterization laboratories, and minimally invasive treatment technologies are supporting market expansion, with advanced coronary intervention technologies accounting for nearly 45% of cardiovascular device investments in 2025.
Download the eBook (ToC)
What Makes Decisions Advisors Research Unique?
- Intelligent Market Research Based on AI for Semiconductors & Optoelectronics
Decisions Advisors offers intelligent market research which includes advanced analysis of infrared sensor technologies, optoelectronic semiconductors, AI-driven sensing solutions, and remote sensing. Our research identifies potential areas of business development, technology adoption rates, competitive position analysis, and important strategic changes in South Korea Remote Sensing Infrared Light Emitting Diode Market.
- Highly Effective Research Approaches with Accurate Forecast Analysis
The research process uses advanced methodologies such as primary research interview approaches, industry research, tracking the semiconductor value chain, and data triangulation to deliver accurate market sizing, CAGR forecasting, investment analysis, and technology forecasting. The study examines the demand for semiconductor solutions in automotive electronics, industrial automation, health care monitoring, and smart surveillance applications in South Korea.
- Highly Competitive Environment Analysis
In-depth analysis of key infrared LED players, optoelectronic semiconductor innovations, AI-enabled sensing solutions, product launch activities, and collaborations is included in the report. The report also covers semiconductor regulations, technology research and development analysis, smart sensor infrastructure, and new opportunities available in the South Korea Remote Sensing Infrared Light Emitting Diode Market.
Competitive Analysis:
The report offers the appropriate analysis of the key organizations/companies involved within the United States Drug Eluting Stent Market, along with a comparative evaluation primarily based on their product of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.
Top Companies United States Drug Eluting Stent Market
- Abbott Laboratories
- Boston Scientific Corporation
- Medtronic plc
- Terumo Corporation
- Biotronik SE & Co. KG
- B. Braun Melsungen AG
- MicroPort Scientific Corporation
- Cook Medical
- Meril Life Sciences Pvt. Ltd.
- Alvimedica
Recent Developments:
- In May 2025, Abbott expanded its portfolio of next-generation drug-eluting stents featuring enhanced polymer coatings and improved long-term vessel healing for patients undergoing coronary interventions.
- In February 2025, Boston Scientific introduced advanced drug-eluting stent technology designed to improve deliverability, reduce restenosis risk, and enhance procedural efficiency during complex coronary artery interventions.
Market Segmentation:
United States Drug Eluting Stent Market, By Stent Type
- Everolimus-Eluting Stents
- Zotarolimus-Eluting Stents
- Sirolimus-Eluting Stents
- Paclitaxel-Eluting Stents
- Other Drug-Eluting Stents
United States Drug Eluting Stent Market, By Application
- Coronary Artery Disease
- Acute Myocardial Infarction
- Chronic Total Occlusion
- Other Cardiovascular Interventions
United States Drug Eluting Stent Market, By End User
- Hospitals
- Cardiac Centers
- Ambulatory Surgical Centers
- Specialty Clinics
Expert Views:
The United States Drug Eluting Stent Market is expected to witness steady growth through 2035, supported by the increasing prevalence of cardiovascular diseases, growing preference for minimally invasive coronary interventions, and continuous innovation in stent technologies. Advancements in bioresorbable polymers, AI-assisted interventional cardiology, precision imaging, and next-generation drug delivery systems are anticipated to strengthen long-term market growth. Furthermore, increasing investments in cardiovascular healthcare infrastructure, expanding access to advanced cardiac procedures, and rising awareness regarding early treatment of coronary artery disease are expected to create significant opportunities for medical device manufacturers, healthcare providers, research organizations, and technology developers across the United States.
Author: Govind and Krishna By Decisions Advisors and Consulting